Inspired by the Sanskrit word Shuchi (Pure), we deliver trusted pharmaceutical products focused on purity, wellness, and safety.
Hyaluronic Acid (HA) is a molecule found naturally throughout the human body especially the joint fluid called synovial fluid. However, the HA in your synovial fluid is continuously broken down and replaced over time. During a progression of OA, the HA is broken down faster than it should be regenerating in the synovial fluid.
Hyaluronic Acid is an important component of the synovial fluid. The synovial fluid enables joints to move easily and freely while providing shock absorption in the joint during physical activity. In a healthy joint, the synovial fluid helps to protect bones and other joint tissues from injury and disease. The synovial fluid also supplies oxygen and nutrients and removes carbon dioxide and metabolic wastes from the cartilage cells in the surrounding cartilage.
Zuroflex-HL is a cross-linked, single injection and formulated as high molecular weight, produced by bacterial fermentation using a proprietary strain, indicated for the treatment of osteoarthritis of knee and supplied as a 3 ml pre filled syringe for injection.
Zuroflex-HL offers double mode of action with just ONE injection.
First, it provides mechanical protection to the joint, shock absorbing effect and lubrication.
Secondly, it provides biological effects such as anti-inflammatory, pain relief and protection to the cartilage surface up to six months* as well as replacing diseased synovial fluid and to restore the visco-elasticity loss in the knee joint caused by osteoarthritis (OA).
*Pain relief duration may vary across patient to patient depending on the severity of knee OA stages?
A steroid injection is generally a powerful anti-inflammatory drug to reduce inflammation and provide immediate pain relief. Steroid injection is usually considered if the joint is having acute pain and inflammation. It usually works faster than a hyaluronic acid injection, however, the pain relief doesn’t last as long and has its disadvantages such as making your cartilage wear off faster and making your bone porous.
Studies have shown that steroid injections provide pain relief up to a few weeks and could not be repeated for more than 3 times a year. However, Zuroflex-HL injection can last for 6-12 months* & more and it is safer for repeat dose when needed.
Zuroflex-HL is a single injection treatment, usually called Viscosupplementation injected directly into the knee by a certified doctor, usually a specialist, an orthopedic surgeon, a rheumatologist and Physicians.
Zuroflex-HL treatment does not involve any additional surgery or drugs (other than local anesthesia, a topical spray or an injection under the skin to numb the knee area may be considered by your doctor).
You may start to feel the pain reduction 2-3 weeks after the treatment and the greatest pain reduction can be felt after week 10 to week 14*.
However, pain relief duration may vary across patient to patient depending on the severity of knee OA stages.
Reports shows for mild to moderate stage, patient may experience pain relief up to 6 months while some other patients may experience continuous pain relief beyond 6 months.
*Ha et al. BMC Musculoskeletal Disorders (2017) 18:223
Yes, you can receive Zuroflex-HL treatment more than once. Zuroflex-HL can be repeated safely. (It can be repeated after 6 month)
Zuroflex-HL is an improved formula, having high concentration 90 mg in 3 ml, single injection. Zuroflex-HL is the 3rd generation of the Hyruan family of HA injections manufactured by HTL Biotechnology, France.
One of the more recent study* shows patients who received 5 or more courses of hyaluronic acid treatment delayed their knee replacement operation by an average of 3.6 years. However, patients without hyaluronic acid treatment had their knee replacement surgery after an average of 9 months.
*Altman RD, Manjoo A, Fierlinger A, Niazi F, Nicholls M. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord. 2015 Oct 26;16:321. doi: 10.1186/s12891-015-0775-z. PMID: 26503103; PMCID: PMC4621876.